US FDA invites companies to participate in drug names pilot
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is inviting pharmaceutical and biotech companies to participate in its much-anticipated pilot programme on the evaluation of drug proprietary names. Under the pilot, companies will be able to check in advance whether their proposed invented trade names are likely to be acceptable to the FDA1,2.